Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the recipient of a significant drop in short interest in the month of August. As of August 14th, there was short interest totaling 14,245 shares, a drop of 50.6% from the July 30th total of 28,818 shares. Based on an average daily volume of 345,411 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Analyst Ratings Changes

Several research analysts have recently issued reports on CHGCY shares. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Finally, UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Chugai Pharmaceutical has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

Shares of OTCMKTS:CHGCY traded up $0.16 during trading on Friday, reaching $21.82. 117,081 shares of the company’s stock traded hands, compared to its average volume of 208,202. The stock has a market capitalization of $71.82 billion, a P/E ratio of 23.72 and a beta of 0.60. Chugai Pharmaceutical has a 12 month low of $20.43 and a 12 month high of $34.84. The company has a 50 day moving average of $22.25 and a 200-day moving average of $25.43.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The business had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Equities research analysts predict that Chugai Pharmaceutical will post 0.96 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.